Physician profile
Eric Mullins
NPI 1225238389
$77,650.09
in general payments reported to CMS, 2019-2025
7 companies · $10K in 2025
The $10K reported for 2025 was more than what 85% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,800 · 2021: $10K · 2022: $8,202 · 2023: $20K · 2024: $9,895 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $4,082 · Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,623.75 |
| Travel and Lodging | $4,082.14 |
| Food and Beverage | $1,078.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33,003.12 | 2020-2023 | |
| Novo Nordisk INC | $29,191.73 | 2023-2025 | |
| Shire North American Group INC | $12,637.59 | 2019 | |
| Hema Biologics, LLC | $2,519.90 | 2021 | |
| Genentech USA, INC. | $297.75 | 2024-2025 | Hemlibra |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.